Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast
Authors:
- 1 March 2016
- journal article
- case report
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 152 (3) , 348-2
Abstract
Case Report from JAMA Dermatology — Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor ApremilastKeywords
This publication has 3 references indexed in Scilit:
- New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastDrug Design, Development and Therapy, 2013
- Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level dataPharmacoepidemiology and Drug Safety, 2010
- Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapyJournal of the American Academy of Dermatology, 2008